Changes in metabolic parameters in psoriatic patients treated with secukinumab
Background: Psoriasis is associated with cardiovascular disease and metabolic syndrome but the effects of interleukin (IL)-17A inhibitor treatment on metabolic parameters are unknown. This study aimed to determine the effects of secukinumab on metabolic parameters based on the disease activity and t...
Saved in:
Main Authors: | Hsuan Ning Wang (Author), Yu Huei Huang (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2020-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Eczematous eruption during bimekizumab treatment in a psoriatic patient previously treated with secukinumab
by: Gennaro Marco Falco, et al.
Published: (2024) -
Secukinumab for ankylosing spondylitis and psoriatic arthritis
by: Lubrano E, et al.
Published: (2016) -
Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis
by: Elena Conesa-Nicolás, et al.
Published: (2021) -
Changes in metabolic parameters in psoriasis patients treated with interleukin-12/23 blockade (ustekinumab)
by: Chau Yee Ng, et al.
Published: (2020) -
Paradoxical flare of psoriasis, psoriatic spondyloarthritis, and psoriatic uveitis after switching from infliximab to secukinumab
by: Peiqi Su, et al.
Published: (2017)